GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CellaVision AB (STU:C26) » Definitions » Cyclically Adjusted PB Ratio

CellaVision AB (STU:C26) Cyclically Adjusted PB Ratio : 11.80 (As of Jan. 19, 2025)


View and export this data going back to 2017. Start your Free Trial

What is CellaVision AB Cyclically Adjusted PB Ratio?

As of today (2025-01-19), CellaVision AB's current share price is €19.36. CellaVision AB's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2024 was €1.64. CellaVision AB's Cyclically Adjusted PB Ratio for today is 11.80.

The historical rank and industry rank for CellaVision AB's Cyclically Adjusted PB Ratio or its related term are showing as below:

STU:C26' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 7.57   Med: 29.77   Max: 53.92
Current: 11.88

During the past years, CellaVision AB's highest Cyclically Adjusted PB Ratio was 53.92. The lowest was 7.57. And the median was 29.77.

STU:C26's Cyclically Adjusted PB Ratio is ranked worse than
92.17% of 447 companies
in the Medical Devices & Instruments industry
Industry Median: 2.01 vs STU:C26: 11.88

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

CellaVision AB's adjusted book value per share data for the three months ended in Sep. 2024 was €2.836. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €1.64 for the trailing ten years ended in Sep. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


CellaVision AB Cyclically Adjusted PB Ratio Historical Data

The historical data trend for CellaVision AB's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CellaVision AB Cyclically Adjusted PB Ratio Chart

CellaVision AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 41.13 33.63 29.45 15.91 12.29

CellaVision AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.32 12.29 13.35 13.50 15.33

Competitive Comparison of CellaVision AB's Cyclically Adjusted PB Ratio

For the Medical Devices subindustry, CellaVision AB's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CellaVision AB's Cyclically Adjusted PB Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, CellaVision AB's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where CellaVision AB's Cyclically Adjusted PB Ratio falls into.



CellaVision AB Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

CellaVision AB's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=19.36/1.64
=11.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CellaVision AB's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2024 is calculated as:

For example, CellaVision AB's adjusted Book Value per Share data for the three months ended in Sep. 2024 was:

Adj_Book=Book Value per Share/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=2.836/132.3043*132.3043
=2.836

Current CPI (Sep. 2024) = 132.3043.

CellaVision AB Quarterly Data

Book Value per Share CPI Adj_Book
201412 0.674 100.225 0.890
201503 0.728 99.950 0.964
201506 0.652 99.995 0.863
201509 0.749 100.228 0.989
201512 0.832 100.276 1.098
201603 0.876 100.751 1.150
201606 0.774 101.019 1.014
201609 0.816 101.138 1.067
201612 0.890 102.022 1.154
201703 1.025 102.022 1.329
201706 0.941 102.752 1.212
201709 0.994 103.279 1.273
201712 1.017 103.793 1.296
201803 1.048 103.962 1.334
201806 0.970 104.875 1.224
201809 1.040 105.679 1.302
201812 1.185 105.912 1.480
201903 1.260 105.886 1.574
201906 1.222 106.742 1.515
201909 1.282 107.214 1.582
201912 1.394 107.766 1.711
202003 1.476 106.563 1.833
202006 1.594 107.498 1.962
202009 1.662 107.635 2.043
202012 1.770 108.296 2.162
202103 1.909 108.360 2.331
202106 1.956 108.928 2.376
202109 2.063 110.338 2.474
202112 2.218 112.486 2.609
202203 2.328 114.825 2.682
202206 2.318 118.384 2.591
202209 2.352 122.296 2.544
202212 2.447 126.365 2.562
202303 2.483 127.042 2.586
202306 2.370 129.407 2.423
202309 2.402 130.224 2.440
202312 2.685 131.912 2.693
202403 2.811 132.205 2.813
202406 2.746 132.716 2.737
202409 2.836 132.304 2.836

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


CellaVision AB  (STU:C26) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


CellaVision AB Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of CellaVision AB's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


CellaVision AB Business Description

Traded in Other Exchanges
Address
Mobilvagen 12, Lund, SWE, 22362
CellaVision AB is engaged in the business of supplying digital solutions for blood and body fluid analysis. Its solutions are based on digital image analysis technology, artificial intelligence, and information technology. The firm's product portfolio consists of CellaVision peripheral blood application, CellaVision advanced RBC application, and CellaVision remote review software. Its customers include mainly large hospital laboratories and commercial laboratories in North America, Europe and China, and Japan. The company derives the majority of its revenue from the sale of analyzers/software.

CellaVision AB Headlines

No Headlines